[Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Mesenchymal-epithelial transition factor (MET) amplification is a key mechanism of acquired resistance to targeted therapies in non-small cell lung cancer (NSCLC).
• This resistance is particularly noted in epidermal growth factor receptor (EGFR)-mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKIs).
• Emerging evidence implicates MET amplification in resistance to TKIs targeting anaplastic lymphoma kinase (ALK), RET, and ROS1 fusions in NSCLC.

Purpose of the Study:

• To review recent research on MET amplification as a resistance driver in oncogene-driven NSCLC.
• To summarize current clinical strategies aimed at overcoming MET-mediated resistance to targeted therapy.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of data on MET amplification in various oncogene-driven NSCLC subtypes.
• Synthesis of information on combination therapies targeting MET and other oncogenic drivers.

Main Results:

• MET amplification confers resistance to EGFR-TKIs in EGFR-mutant NSCLC.
• MET amplification also drives resistance to ALK, RET, and ROS1 inhibitors in respective NSCLC subtypes.
• Combination therapies targeting MET and the primary oncogenic driver are emerging as effective strategies.

Conclusions:

• MET amplification is a significant and versatile resistance mechanism in oncogene-driven NSCLC.
• Targeting MET, often in combination with other TKIs, represents a promising therapeutic approach to overcome acquired resistance.